Bochuan Deng

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Epithelial Mesenchymal Transition

Transforming Growth Factor

Editorial Comment

Pulmonary Fibrosis

Top Venues

ACS pharmacology & translational science

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

This page only lists publications with an associated author ORCID identifier.

Publications

Bochuan Deng, Jiao Zhang, Xiang Zhang, Dan Wang, Lu Cheng, Ping Su, Tingli Yu, Guangjun Bao, Guofeng Li, Liang Hong, Xiaokang Miao, Wenle Yang, Rui Wang, Junqiu Xie
Novel Peptide DR3penA as a Low-Toxicity Antirenal Fibrosis Agent by Suppressing the TGF-β1/miR-212-5p/Low-Density Lipoprotein Receptor Class a Domain Containing 4/Smad Axis. ACS pharmacology & translational science 7 (4) (2024)
Bochuan Deng, Jiao Zhang, Xiang Zhang, Dan Wang, Lu Cheng, Ping Su, Tingli Yu, Guangjun Bao, Guofeng Li, Liang Hong, Xiaokang Miao, Wenle Yang, Rui Wang, Junqiu Xie
Novel Peptide DR3penA as a Low-Toxicity Antirenal Fibrosis Agent by Suppressing the TGF-β1/miR-212-5p/Low-Density Lipoprotein Receptor Class a Domain Containing 4/Smad Axis. ACS pharmacology & translational science 7 (4) (2024)
Bochuan Deng, Jiao Zhang, Xiang Zhang, Dan Wang, Lu Cheng, Ping Su, Tingli Yu, Guangjun Bao, Guofeng Li, Liang Hong, Xiaokang Miao, Wenle Yang, Rui Wang, Junqiu Xie
Novel Peptide DR3penA as a Low-Toxicity Antirenal Fibrosis Agent by Suppressing the TGF-β1/miR-212-5p/Low-Density Lipoprotein Receptor Class a Domain Containing 4/Smad Axis. ACS pharmacology & translational science 7 (4) (2024)
Dan Wang, Bochuan Deng, Lu Cheng, Jieru Li, Xiaomin Guo, Jiao Zhang, Xiang Zhang, Ping Su, Guofeng Li, Xiaokang Miao, Wenle Yang, Junqiu Xie, Rui Wang
The novel peptide DR4penA attenuates the bleomycin- and paraquat-induced pulmonary fibrosis by suppressing the TGF-β/Smad signaling pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 37 (11) (2023)